Prestige Pulls Trastuzumab After EMA Knockback

Formal Withdrawal Of MAA Follows CHMP Negative Opinion And Re-Examination

 
• By Dave Wallace

Prestige Biopharma has formally withdrawn its marketing authorization application for its Tuznue (trastuzumab) biosimilar candidate, following a negative opinion from the EMA’s CHMP as well as a requested re-examination.

Withdrawal wooden blocks letters
Prestige has withdrawn its HD201 trastuzumab candidate in Europe • Source: Shutterstock

More from Biosimilars

More from Products